在多药耐药时代处理肺移植中的抗生素预防：米兰算法。

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2025-01-09 DOI:10.1016/j.transproceed.2024.12.024

Andrea Lombardi , Davide Mangioni , Giulia Renisi , Jacopo Fumagalli , Letizia Morlacchi , Lorenzo Rosso , Alessandro Palleschi , Valeria Rossetti , Mauro Panigada , Chiara Abbruzzese , Lisa Cariani , Annapaola Callegaro , Mario Nosotti , Francesco Blasi , Giacomo Grasselli , Alessandra Bandera

{"title":"在多药耐药时代处理肺移植中的抗生素预防：米兰算法。","authors":"Andrea Lombardi , Davide Mangioni , Giulia Renisi , Jacopo Fumagalli , Letizia Morlacchi , Lorenzo Rosso , Alessandro Palleschi , Valeria Rossetti , Mauro Panigada , Chiara Abbruzzese , Lisa Cariani , Annapaola Callegaro , Mario Nosotti , Francesco Blasi , Giacomo Grasselli , Alessandra Bandera","doi":"10.1016/j.transproceed.2024.12.024","DOIUrl":null,"url":null,"abstract":"<div><div>Infectious complications significantly impact morbidity and mortality following lung transplantation (LuTx), with over 25% of post-transplant deaths attributed to infections. Antibiotic prophylaxis during the surgical procedure is crucial for reducing early infections, though the current use of wide-spectrum antibiotics, especially in cases of multidrug-resistant organisms (MDROs), is contentious and varies widely across centre. This practice raises concerns about antimicrobial resistance (AMR), particularly in immunosuppressed patients requiring lifelong healthcare access. Syndromic multiplex polymerase chain reaction (mPCR) tests, which detect multiple pathogens simultaneously, have shown promise in quickly identifying pathogens and resistance mechanisms, thus enabling targeted treatments. However, their application in LuTx has been limited.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 2","pages":"Pages 339-341"},"PeriodicalIF":0.8000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dealing With Antibiotic Prophylaxis in Lung Transplantation in the Era of Multidrug Resistance: The Milano Algorithm\",\"authors\":\"Andrea Lombardi , Davide Mangioni , Giulia Renisi , Jacopo Fumagalli , Letizia Morlacchi , Lorenzo Rosso , Alessandro Palleschi , Valeria Rossetti , Mauro Panigada , Chiara Abbruzzese , Lisa Cariani , Annapaola Callegaro , Mario Nosotti , Francesco Blasi , Giacomo Grasselli , Alessandra Bandera\",\"doi\":\"10.1016/j.transproceed.2024.12.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Infectious complications significantly impact morbidity and mortality following lung transplantation (LuTx), with over 25% of post-transplant deaths attributed to infections. Antibiotic prophylaxis during the surgical procedure is crucial for reducing early infections, though the current use of wide-spectrum antibiotics, especially in cases of multidrug-resistant organisms (MDROs), is contentious and varies widely across centre. This practice raises concerns about antimicrobial resistance (AMR), particularly in immunosuppressed patients requiring lifelong healthcare access. Syndromic multiplex polymerase chain reaction (mPCR) tests, which detect multiple pathogens simultaneously, have shown promise in quickly identifying pathogens and resistance mechanisms, thus enabling targeted treatments. However, their application in LuTx has been limited.</div></div>\",\"PeriodicalId\":23246,\"journal\":{\"name\":\"Transplantation proceedings\",\"volume\":\"57 2\",\"pages\":\"Pages 339-341\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-01-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplantation proceedings\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0041134524006870\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041134524006870","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

感染并发症显著影响肺移植（LuTx）后的发病率和死亡率，超过25%的移植后死亡归因于感染。手术过程中的抗生素预防对于减少早期感染至关重要，尽管目前广谱抗生素的使用，特别是在耐多药生物（MDROs）的情况下，存在争议并且各中心差异很大。这种做法引起了对抗菌素耐药性（AMR）的关注，特别是在需要终身获得医疗保健的免疫抑制患者中。同时检测多种病原体的综合征多重聚合酶链反应（mPCR）试验在快速识别病原体和耐药机制方面显示出希望，从而实现靶向治疗。然而，它们在LuTx中的应用受到了限制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dealing With Antibiotic Prophylaxis in Lung Transplantation in the Era of Multidrug Resistance: The Milano Algorithm

Infectious complications significantly impact morbidity and mortality following lung transplantation (LuTx), with over 25% of post-transplant deaths attributed to infections. Antibiotic prophylaxis during the surgical procedure is crucial for reducing early infections, though the current use of wide-spectrum antibiotics, especially in cases of multidrug-resistant organisms (MDROs), is contentious and varies widely across centre. This practice raises concerns about antimicrobial resistance (AMR), particularly in immunosuppressed patients requiring lifelong healthcare access. Syndromic multiplex polymerase chain reaction (mPCR) tests, which detect multiple pathogens simultaneously, have shown promise in quickly identifying pathogens and resistance mechanisms, thus enabling targeted treatments. However, their application in LuTx has been limited.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.